semaglutide compounding news FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products Compound versions of GLP-1 drugs

Novo Nordisk's internal once-weekly peptide triple agonist, distinct from UBT-251

Iqbal J, Wu H, Hu N, Zhou Y, Li L, Xiao F, et al

Early signs include: Increased appetite with weight loss Increased thirst and urination Increase in vocalization Palpable mass in the neck/enlarged thyroid gland A sudden increase in energy/hyperactivity Behavioral changes (more anxious/fractious/aggressive) Gastrointestinal signs such as vomiting and diarrhea Reduction in grooming activities/loss of coat condition Alopecia (hair loss) Racing heart rate Sleep disturbances These symptoms will progress and become more profound

We used an active-comparator, incident new-user design to emulate the target trial